摘要
目的探讨叉头框转录蛋白1(FOXP1)在弥漫性大B细胞淋巴瘤(DLBCL)中的表达及其与DLBCL临床病理特征和预后的关系。方法用免疫组织化学En Vision法检测85例DLBCL组织中FOXP1蛋白的表达情况,并分析FOXP1与临床病理特征及预后的关系。结果 85例DLBCL组织中FOXP1的阳性表达率为71.8%(61/85),FOXP1表达与年龄、PS评分、乳酸脱氢酶(LDH)水平、国际预后指数评分、病理类型密切相关(P<0.05)。在生发中心型(GCB)DLBCL中FOXP1阳性和阴性表达者的无病生存期(PFS)为13个月和44个月(P=0.002),总生存期(OS)为28个月和50个月(P=0.003);而在非生发中心型(non-GCB)中FOXP1表达与生存预后无关(P>0.05)。单因素分析显示分期、LDH水平、有无B症状以及FOXP1表达与DLBCL患者的PFS和OS均相关(P<0.05),Cox多因素回归分析显示分期(95%CI:1.410～4.415,P=0.02)和FOXP1表达(95%CI:0.143～0.734,P=0.007)是PFS的独立预测因素。结论 FOXP1蛋白有可能是DLBCL的一个重要的预后指标,尤其在GCB型DLBCL中FOXP1蛋白阳性表达提示预后不佳。
Objective To investigate the clinical and prognostic significance of forkhead box protein1（FOXP1） expression in diffuse large B-cell lymphoma（DLBCL）.Methods Tumor tissues from 85 DLBCL were analyzed for FOXP1 protein expression using immunohistochemistry and the correlation with clinicopathologic features and prognosis.Results Of all the 85 patients,61（71.8%） showed FOXP1 positive expression,and the expression rate of FOXP1 protein in DLBCL had relation with ages,PS score,LDH,IPI and pathologic types.FOXP1 positive expression had significantly worse progress free survival（PFS） compared to FOXP1 negative expression（13 months vs.44 months,P=0.002） and overall survival（OS）（28 months vs.50 months,P=0.003） in the GCB phenotype.However,FOXP1 in non-GCB phenotype was not related to prognosis.Univariate analysis identified that FOXP1,stage,LDH and B symptoms were prognostic factors of PFS and OS.Multivariate Cox regression analysis identified that stage（95%CI：1.410-4.415,P=0.002） and FOXP1 expression（95%CI：0.143-0.734,P=0.007） were independent prognostic factors of PFS,but not OS in DLBCL.Conclusion FOXP1 expression in DLBCL tissues may be a valuable biomarker for predicting the survival of DLBCL patients,especially in GCB phenotype.
出处
《临床肿瘤学杂志》
CAS
2012年第4期339-342,共4页
Chinese Clinical Oncology
